Beryllium-induced tumor necrosis factor-α production by CD4 + T cells is mediated by HLA-DP

American Journal of Respiratory Cell and Molecular Biology

Volumn 31, Issue 1, 2004, Pages 122-130

  Sawyer, Richard T ^a   Parsons, Charles E ^b   Fontenot, Andrew P ^b   Maier, Lisa A ^b   Gillespie, May M ^b   Gottschall, E Brigitte ^b   Silveira, Lori ^b   Newman, Lee S ^b  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BERYLLIUM; CD3 ANTIGEN; CD4 ANTIGEN; CYTOKINE; HLA DP ANTIGEN; HLA DR3 ANTIGEN; MESSENGER RNA; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ALLELE; ARTICLE; BERYLLIOSIS; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; FEMALE; GENETIC SUSCEPTIBILITY; GENETIC TRANSCRIPTION; GRANULOMATOSIS; HUMAN; HUMAN CELL; LUNG LAVAGE; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; SARCOIDOSIS; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH1 CELL; UPREGULATION;

ANTIBODIES, MONOCLONAL; BERYLLIOSIS; BERYLLIUM; BRONCHOALVEOLAR LAVAGE FLUID; CD4-POSITIVE T-LYMPHOCYTES; CELL DIVISION; CYTOKINES; FEMALE; HLA-DP ANTIGENS; HUMANS; INFLAMMATION MEDIATORS; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; RECEPTORS, ANTIGEN, T-CELL; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 3042836328     PISSN: 10441549     EISSN: None     Source Type: Journal    
DOI: 10.1165/rcmb.2003-0336OC     Document Type: Article

References (45)

1. Sawyer, R. T., L. A. Maier, L. A. Kittle, and L. S. Newman. 2002. Chronic beryllium disease: a model interaction between innate and acquired immunity. Int. Immunopharmacol. 2:249-261.
2. + T cells in patients with chronic beryllium disease. J. Clin. Invest. 110:1473-1482.
3. Tinkle, S. S., L. A. Kittle, B. A. Schumacher, and L. S. Newman. 1997. Beryllium induces IL-2 and IFN-γ in berylliosis. J. Immunol. 158:518-526.
4. Tinkle, S. S., and L. S. Newman. 1997. Beryllium-stimulated release of tumor necrosis factor-α, interleukin-6, and their soluble receptors in chronic beryllium disease. Am. J. Respir. Crit. Care Med. 156:1884-1891.
5. Maier, L. A., R. T. Sawyer, S. S. Tinkle, L. A. Kittle, E. A. Barker, R. Balkissoon, C. S. Rose, and L. S. Newman. 2001. IL-4 fails to regulate in vitro beryllium-induced cytokines in berylliosis. Eur. Respir. J. 17:403-415.
6. Maier, L. A., R. T. Sawyer, R. A. Bauer, L. A. Kittle, P. Lympany, D. McGrath, R. DuBois, E. Daniloff, C. S. Rose, and L. S. Newman. 2001. High beryllium-stimulated TNF-α is associated with the -308 TNF-α promoter polymorphism and with clinical severity in chronic beryllium disease. Am. J. Respir. Crit. Care Med. 164:1192-1199.
7. Richeldi, L., R. Sorrentino, and C. Saltini. 1999. HLA-DPB1 glutamate 69: a genetic marker of beryllium disease. Science 262:242-244.
8. Wang, Z., S. P. White, M. Petrovic, O. L. Tatum, L. S. Newman, L. A. Maier, and M. L. Marrone. 1999. Differential susceptibilities to chronic beryllium disease contributed by different glu69 HLA-DPB1 and -DPA1 alleles. J. Immunol. 163:1647-1653.
9. Rossman, M. D., J. Stubbs, C. W. Lee. E. Argyris, E. Magira, and D. Monos. 2002. Human leukocyte antigen class II amino acid epitopes: susceptibility and progression markers for beryllium hypersensitivity. Am. J. Respir. Crit. Care Med. 165:788-794.
10. Fontenot, A. P., L. S. Newman, and B. L. Kotzin. 2001. Chronic beryllium disease: T cell recognition of a metal presented by HLA-DP. Clin. Immunol 100:4-14.
11. + T cells underlies disease-susceptibility HLA-DP alleles in chronic beryllium disease. Proc. Natl. Acad. Sci. USA 97:12717-12722.
12. Lombardi, G., C. Germain, J. Uren, R. Fiorillo, R. M. DuBois, W. Jones-Williams, C. Saltini, R. Sorrentino, and R. Lechler. 2001. HLA-DP allele-specific T cell responses to beryllium account for DP-associated susceptibility to chronic beryllium disease. J. Immunol. 166:3549-3555.
13. Saltini, C., K. Winestock, M. Kirby, P. Pinkston, and R. G. Crystal. 1989. Maintenance of alveolitis in patients with chronic beryllium disease by beryllium-specific helper T cells. N. Engl. J. Med. 320:1103-1109.
14. Litton, M. J., B. Sander, M. Murphy, A. O'Garra, and J. S. Abrams. 1994. Early expression of cytokines in lymph nodes after treatment in vivo with Staphylococcus enterotoxin B. J. Immunol. Methods 175:47-58.
15. Alegre, M., P. Vandenabeele. V. Flamand, M. Moser, O. Leo, D. Abramowicz, J. Urbain, W. Fiers, and M. Goldman. 1990. Hypothermia and hypoglycemia induced by anti-CD3 monoclonal antibody in mice: role of tumor necrosis factor. Eur. J. Immunol. 20:707-710.
16. Ferran, C., K. Sheehan, M. Dy, R. Schreiber, S. Merite, P. Landais, L. H. Noel, G. Grau, J. Bluestone, and J. F. Bach. 1990. Cytokine-related syndrome following injection of anti-CD3 monoclonal antibody: Further evidence for transient in vivo T cell activation. Eur. J. Immunol. 20:509-515.
17. Tracey, K. J., and A. Cerami. 1993. Tumor necrosis factor, other cytokines and disease. Annu. Rev. Cell Biol. 9:317-343.
18. Yang, Y., J. F. Chang, J. R. Parnes, and C. G. Fathman. 1998. T cell receptor (TCR) engagement leads to activation-induced splicing of tumor necrosis factor (TNF) nuclear pre-mRNA. J. Exp. Med. 188:246-254.
19. Swanson, B. J., M. Murakami, T. C. Mitchell, J. Kappler, and P. Marrack. 2002. RANTES production by memory phenotype T cells is controlled by a posttranscriptional, TCR-dependent process. Immunity 17:605-615.
20. Amicosante, M., F. Berretta, A. Franchi, P. Rogliani, C. Gotti, M. Losi, R. Dweik, and C. Saltini. 2002. HLA-DP-unrestricted TNF-α release by beryllium-stimulated peripheral blood mononuclear cells. Eur. Respir. J. 20: 1174-1178.
21. Newman, L. S., K. Kreiss, T. R. King, Jr., S. Seay, and P. A. Campbell. 1989. Pathologic and immunologic alterations in early stages of beryllium disease: re-examination of disease definition and natural history. Am. Rev. Respir. Dis. 139:1479-1486.
22. Mroz, M. M., K. Kreiss, D. C. Lezotte, P. A. Campbell, and L. S. Newman. 1991. Re-examination of the blood lymphocyte transformation test in the diagnosis of chronic beryllium disease. J. Allergy Clin. Immunol. 88:54-60.
23. Hunninghake, G. W., U. Costabel, M. Ando, R. Baughman, J. F. Cordier, R. Du Bois, A. Eklund, M. Kitaichi, J. Lynch, G. Rizzato, C. Rose, R. Selroos, G. Semenzato, and O. P. Sharma. 1999. Statement on sarcoidosis. Am. J. Respir. Crit. Care Med. 160:736-755.
24. Ferris, B. G. 1978. Epidemiology standardization project. Am. Rev. Respir. Dis. 118:1-120.
25. Watson, A. J., R. DeMars, I. S. Trowbridge, and F. H. Bach. 1983. Detection of a novel human class II HLA antigen. Nature 304:358-361.
26. Watters, L. C., M. I. Schwartz, and R. M. Cherniak. 1997. Idiopathic pulmonary fibrosis: pretreatment bronchoalveolar lavage cellular constituents and their relationship with lung histopathology and clinical response to therapy. Am. Rev. Respir. Dis. 135:696-704.
27. + T cell frequencies by flow cytometery; evidence for a novel, antigen-specific homeostatic mechanism in HIV-associated immunodeficiency. J. Clin. Invest. 99: 1739-1750.
28. + T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nat. Med. 5:518-525.
29. + lung and blood T cells in sarcoidosis. Am. J. Respir. Crit. Care Med. 163:115-121.
30. Kreiss, K., M. M. Mroz, B. Zhen, J. W. Martyny, and L. S. Newman. 1993. Epidemiology of beryllium sensitization and disease in nuclear workers. Am. Rev. Respir. Dis. 148:985-991.
31. Hance, A. J., F. Basset, G. Saumon, C. Danel, D. Valeyre, J. P. Battesti, J. Chretien, and R. Georges. 2003. Smoking and interstitial lung disease: the effect of cigarette smoking on the incidence of pulmonary histiocytosis X and sarcoidosis. Ann. N.Y. Acad. Sci. 465:643-656.
32. Murin, S., K. S. Bilello, and R. Matthay. 2000. Other smoking-affected pulmonary diseases. Clin. Chest Med. 21:121-137, ix.
33. Maier, L. A., D. S. McGrath, H. Sato, P. Lympany, K. Walsh, R. duBois, L. Silveira, A. P. Fontenot, R. T. Sawyer, E. Wilcox, and L. S. Newman. 2003. Influence of MHC class II susceptibility to beryllium sensitization and chronic beryllium disease. J. Immunol. 171:6910-6918.
34. Bost, T. W., D. W. G. Riches, B. Schumacher, P. C. Carre, T. Z. Kahn, J. A. Martinez, and L. S. Newman. 1994. Alveolar macrophages from patients with beryllium disease and sarcoidosis express increased levels of mRNA for tumor necrosis factor-α and interleukin-6 but not interleukin 1β. Am. J. Respir. Cell Mol. Biol. 10:506-513.
35. Sawyer, R. T., H. Hamada, L. A. Kittle, and L. S. Newman. 2000. Beryllium-stimulated tumor necrosis factor-a production by a mouse hybrid macrophage cell line. Toxicology 143:235-247.
36. Hamada, H., R. T. Sawyer, L. A. Kittle, and L. S. Newman. 2000. Beryllium stimulation does not activate transcription factors in a mouse hybrid macrophage cell line. Toxicology 143:249-261.
37. Galbraith, G. M., J. P. Pandey, M. G. Schmidt, P. Arnaud, and J. M. Goust. 1996. Tumor necrosis factor alpha gene expression in human monocytic THP-1 cells exposed to beryllium. Arch. Environ. Health 51:29-33.
38. Kreiss, K., M. M. Mroz, B. Zhen, H. Wiedmann, and B. Barna. 1997. Risks of beryllium disease related to work processes at a metal, alloy, and oxide production plant. Occup. Environ. Med. 54:605-612.
39. Stedman, R. L. 1968. The chemical composition of tobacco and tobacco smoke. Chem. Rev. 68:153-207.
40. Mooney, N. A., C. Grillot-Courvalin, C. Hivroz, L. Y. Ju, and D. Charron. 1990. Early biochemical events after MHC class II-mediated signaling on human B lymphocytes. J. Immunol. 145:2070-2076.
41. Lane, P. J. L., F. M. McConnell, G. L. Schieven, E. A. Clark, and J. A. Ledbetter. 1990. The role of class II molecules in human B cell activation. J. Immunol. 144:3684-3692.
42. Cambier, J. C., D. C. Morrison, M. M. Chien, and K. R. Lehmann. 1991. Modeling of T cell contact-dependent B cell activation. J. Immunol. 146: 2075-2082.
43. Andre, P., J. C. Cambier, T. K. Wade, T. Raetz, and F. W. Wade. 1994. Distinct structural compartmentalization of the signal transduction functions of major histocompatibility complex class II (Ia) molecules. J. Exp. Med. 179: 763-768.
44. Lang, P., J. C. Stolpa, B. A. Freibert, F. Crawford, J. Kappler, A. Kupfer, and J. C. Cambier. 2001. TCR-induced transmembrane signaling by peptide/ MHC class II via associated Ig-α/β dimmers. Science 291:1537-1540.
45. Jarrous, N., F. Osman, and R. Kaempfer. 1996. 2-Aminopurine selectively inhibits splicing of tumor necrosis factor alpha mRNA. Mol. Cell. Biol. 16: 2814-2822.